Matthew Hellmann
Hematology & Oncology · New York, NYNPI 1881853422
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (57.4%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 16 manufacturers reported payments, led by Merck at 49.1% of the total. Reporting peaked in 2019 at $118,339 and has fallen 83.4% since, to $19,650 in 2022. Among hematology & oncology clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 110 payments — averaging $2070.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$112K
- E.r. Squibb & Sons, L.L.C.$29K
- AstraZeneca$19K
- Genentech, Inc.$19K
- F. Hoffmann-la Roche AG$12K
- Astrazeneca UK Limited$8K
- plus $30K from 10 others
Across 216 payments — averaging $13,111 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$1.1M
- Genentech, Inc.$1M
- AstraZeneca$305K
- E.r. Squibb & Sons, L.L.C.$238K
- Eli Lilly$166K
- Roche Products Limited$38K
- plus $1K from 1 others
What the payments were for
- Consulting fees$130,70757%
- Speaking & faculty fees$40,50818%
- Grants$18,7508%
- Travel & lodging$36,34416%
- Food & beverage$1,4741%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 48 | $111,942 |
| E.r. Squibb & Sons, L.L.C. | 17 | $29,094 |
| AstraZeneca | 14 | $18,830 |
| Genentech, Inc. | 1 | $18,750 |
| F. Hoffmann-la Roche AG | 6 | $11,578 |
| Astrazeneca UK Limited | 5 | $7,980 |
| Regeneron | 1 | $5,895 |
| Bayer | 2 | $5,080 |
| Janssen Global Services, LLC | 1 | $4,960 |
| Sanofi | 2 | $4,578 |
| Eisai Inc. | 1 | $4,375 |
| Daiichi Sankyo Inc. | 1 | $2,055 |
| Eli Lilly | 2 | $1,548 |
| Astrazeneca AB | 7 | $1,029 |
| Bristol Myers Squibb | 1 | $78 |
| Collegium Pharmaceutical, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- KEYTRUDA$49,483
- LENVIMA$14,106
- LIBTAYO$7,857
- OPDIVO$7,282
- Non-Covered Product$7,173
- IMFINZI$5,320
- Non-Covered$5,080
- TAGRISSO$4,655
- TECENTRIQ$4,405
How this compares
$227,783 in reported general payments places this provider in the 95th percentile of 967 hematology & oncology providers in New York.
Other hematology & oncology in New York
- Michael SchusterNew York$1.6M
- Charles SawyersNew York$1.6M
- Manuel Hidalgo-MedinaNew York$1.4M
- Ross LevineNew York$968K
- Joshua SabariNew York$761K
- Gail RobozNew York$738K
- Jeffrey LaurenceNew York$640K
- John AllanNew York$580K
- Ilan ShapiraNew York$475K
- John MascarenhasNew York$456K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.